77 related articles for article (PubMed ID: 19948216)
1. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
3. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.
Greene AC; Lord SJ; Tian A; Rhodes C; Kai H; Groves JT
Biophys J; 2014 May; 106(10):2196-205. PubMed ID: 24853748
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size.
Zapata-Mercado E; Biener G; McKenzie DM; Wimley WC; Pasquale EB; Raicu V; Hristova K
J Biol Chem; 2022 Oct; 298(10):102370. PubMed ID: 35970390
[TBL] [Abstract][Full Text] [Related]
6. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
Faoro L; Singleton PA; Cervantes GM; Lennon FE; Choong NW; Kanteti R; Ferguson BD; Husain AN; Tretiakova MS; Ramnath N; Vokes EE; Salgia R
J Biol Chem; 2010 Jun; 285(24):18575-85. PubMed ID: 20360610
[TBL] [Abstract][Full Text] [Related]
7. EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer.
Li Y; Peng Q; Wang L
Aging (Albany NY); 2023 Nov; 15(22):12952-12965. PubMed ID: 37980165
[TBL] [Abstract][Full Text] [Related]
8. Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly.
Shi X; Lingerak R; Herting CJ; Ge Y; Kim S; Toth P; Wang W; Brown BP; Meiler J; Sossey-Alaoui K; Buck M; Himanen J; Hambardzumyan D; Nikolov DB; Smith AW; Wang B
Science; 2023 Dec; 382(6674):1042-1050. PubMed ID: 37972196
[TBL] [Abstract][Full Text] [Related]
9. Receptor Tyrosine Kinase EPHA2 Drives Epidermal Differentiation through Regulation of EGFR Signaling.
Perez White BE; Cable CJ; Shi B; Ventrella R; Kaplan N; Kobeissi A; Higuchi Y; Balu A; Murphy ZR; Kumar P; Getsios S
J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38520417
[TBL] [Abstract][Full Text] [Related]
10. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
[TBL] [Abstract][Full Text] [Related]
11. Filamin A forms a complex with EphA2 and regulates EphA2 serine 897 phosphorylation and glioblastoma cell proliferation.
Tamura Y; Nakamizo Y; Watanabe Y; Kimura I; Katoh H
Biochem Biophys Res Commun; 2022 Mar; 597():64-70. PubMed ID: 35124461
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol (4,5)-bisphosphate drives the formation of EGFR and EphA2 complexes.
Singh PK; Rybak JA; Schuck RJ; Barrera FN; Smith AW
bioRxiv; 2024 May; ():. PubMed ID: 38746348
[TBL] [Abstract][Full Text] [Related]
13. Correction to: EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2024 May; 45(5):1093-1094. PubMed ID: 38228911
[No Abstract] [Full Text] [Related]
14. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
15. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
16. Eph receptor and ephrin function in breast, gut, and skin epithelia.
Perez White BE; Getsios S
Cell Adh Migr; 2014; 8(4):327-38. PubMed ID: 25482622
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.
Ståhl S; Kaminskyy VO; Efazat G; Hyrslova Vaculova A; Rodriguez-Nieto S; Moshfegh A; Lewensohn R; Viktorsson K; Zhivotovsky B
Cell Death Dis; 2013 Jan; 4(1):e454. PubMed ID: 23303128
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
20. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
